“…Drug development issues associated with HDPs, including susceptibility to proteolysis, high production costs, and, in some case, low to moderate activity under physiological salt conditions, prevent their direct introduction as clinical agents [ 8 ]. In order to overcome these deficiencies, an extensive amount of research has been directed towards the synthesis and biological evaluation of synthetic mimics of antimicrobial peptides, so-called SMAMPs [ 9 , 10 , 11 , 12 , 13 , 14 , 15 ]. Numerous different structural classes of SMAMPs have been identified, including shorter peptides (e.g., LTX-109 ( 1 )), sterols (e.g., squalamine ( 2 )), and hydantoins (e.g., 3 ) ( Figure 1 ) [ 15 , 16 , 17 ].…”